宫颈成熟球囊与口服米索前列醇用于小于胎龄儿引产:回顾性多中心研究
该回顾性多中心队列研究纳入848例估计胎儿体重低于第10百分位且Bishop评分低于7分的单胎妊娠,比较口服米索前列醇与宫颈成熟球囊引产的母儿结局;调整后两组剖宫产率无显著差异,米索前列醇组手术阴道分娩和缩宫素加强需求更少,作者认为口服米索前列醇是安全有效的选择。
要点
- 对于小于胎龄儿或晚发型胎儿生长受限引产,口服米索前列醇与宫颈成熟球囊的剖宫产率无显著差异(aOR 1.29,95%CI 0.82-2.04)。
- 米索前列醇组手术阴道分娩(aOR 0.33,95%CI 0.18-0.64)和缩宫素加强(aOR 0.04,95%CI 0.03-0.07)均少于球囊组。
- 米索前列醇组子宫过度刺激更常见,但未增加胎儿窘迫相关剖宫产或不良新生儿结局。
核心结论
- 在晚发型胎儿生长受限或小于胎龄儿妊娠中,口服米索前列醇与单纯机械性宫颈成熟相比未增加剖宫产风险,且与手术干预和产程加强需求减少相关。
研究设计与样本
- 回顾性多中心队列研究,纳入三个欧洲三级中心共848例单胎妊娠,估计胎儿体重低于第10百分位且Bishop评分低于7分,孕周≥37周因疑似小于胎龄儿或晚发型胎儿生长受限引产。
诊断标准与关键数值
- 主要结局剖宫产率:米索前列醇组与球囊组比较,调整后OR 1.29(95%CI 0.82-2.04),无显著差异。
- 手术阴道分娩:米索前列醇组较球囊组调整后OR 0.33(95%CI 0.18-0.64)。
- 缩宫素加强:米索前列醇组较球囊组调整后OR 0.04(95%CI 0.03-0.07)。
- 引产开始后24小时内自然阴道分娩:米索前列醇组较球囊组调整后OR 0.49(95%CI 0.33-0.74)。
临床应用与阅片要点
- 对于小于胎龄儿或晚发型胎儿生长受限需引产的孕妇,口服米索前列醇未增加剖宫产风险,可作为引产选择之一。
- 米索前列醇组子宫过度刺激更常见,但未伴随胎儿窘迫相关剖宫产或不良新生儿结局增加。
- 作者认为这些发现支持口服米索前列醇作为该高危人群引产的安全有效选择。
- 作者指出需要随机对照试验来证实这些结果。
局限性
- 原文为回顾性多中心队列研究。
- 两组基线特征存在差异,米索前列醇组年龄更大、初产妇更多且引产孕周更晚。
- 作者指出需要随机对照试验来证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the maternal and neonatal outcomes following induction of labor (IOL) using oral misoprostol vs mechanical cervical ripening using a cervical ripening balloon (CRB) in singleton pregnancies complicated by small-for-gestational age (SGA), including those with late-onset fetal growth restriction (FGR).
METHODS: This was a retrospective multicenter cohort study of women with a singleton pregnancy with estimated fetal weight < 10th percentile and a Bishop score of < 7, who underwent IOL ≥ 37 weeks' gestation for suspected SGA or late-onset FGR in one of three European tertiary centers. Participants were assigned to one of two groups depending on whether they underwent cervical ripening using a CRB without pharmacologic agents (CRB-only group) or received oral misoprostol with or without a CRB (misoprostol group). Women who had had a prior Cesarean delivery (CD), those who received vaginal misoprostol and those with early-onset FGR, fetal structural anomalies or contraindications to vaginal delivery were excluded. The primary outcome was CD. Secondary outcomes included spontaneous vaginal delivery (SVD) within 24 h after starting IOL, operative vaginal delivery (OVD), oxytocin augmentation, uterine tachysystole and neonatal outcomes. Inverse probability of treatment weighting was used to account for baseline differences and doubly robust estimation was used to adjust for confounders.
RESULTS: A total of 848 women was included in the analysis, of whom 431 (50.8%) received a CRB only and 417 (49.2%) received oral misoprostol with or without a CRB. Baseline characteristics differed between the two groups, with women in the misoprostol group being older, more often nulliparous and undergoing IOL later in gestation. After adjustment, there was no significant difference in the rate of CD between the two groups (adjusted odds ratio (aOR), 1.29 (95% CI, 0.82-2.04)). Women receiving misoprostol were significantly less likely to undergo OVD (aOR, 0.33 (95% CI, 0.18-0.64)) or require oxytocin augmentation (aOR, 0.04 (95% CI, 0.03-0.07)) compared with the CRB-only group. SVD within 24 h after starting IOL was also less likely in the misoprostol group (aOR, 0.49 (95% CI, 0.33-0.74)). Uterine tachysystole occurred more frequently in the misoprostol ± CRB group, but this was not associated with higher rates of CD for fetal distress or adverse neonatal outcomes. The rate of admission to the neonatal intensive care unit was similar between the two groups. Subgroup analysis in pregnancies with confirmed late-onset FGR yielded comparable findings.
CONCLUSIONS: In pregnancies complicated by late-onset FGR or SGA, oral misoprostol did not increase the risk of CD compared with mechanical cervical ripening only, and was associated with a reduced need for operative interventions and labor augmentation. These findings support the use of oral misoprostol as a safe and effective option for IOL in this high-risk population. Randomized controlled trials are needed to confirm these results. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Zaccaria G, Dutemeyer V, Carlin A, et al. Cervical ripening balloon vs oral misoprostol for induction of labor in small-for-gestational age: retrospective multicenter study. Ultrasound Obstet Gynecol. 2025. PMID: 41305845. doi:10.1002/uog.70142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。